Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn's Disease

Stock Information for Ventyx Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.